Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Depreciation and Depletion (2016 - 2025)

Historic Depreciation and Depletion for Marimed (MRMD) over the last 10 years, with Q3 2025 value amounting to $2.1 million.

  • Marimed's Depreciation and Depletion rose 1666.67% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.2 million, marking a year-over-year increase of 1081.08%. This contributed to the annual value of $7.9 million for FY2024, which is 4363.64% up from last year.
  • Marimed's Depreciation and Depletion amounted to $2.1 million in Q3 2025, which was up 1666.67% from $2.1 million recorded in Q2 2025.
  • Over the past 5 years, Marimed's Depreciation and Depletion peaked at $2.2 million during Q4 2024, and registered a low of $462000.0 during Q1 2021.
  • Moreover, its 5-year median value for Depreciation and Depletion was $1.2 million (2023), whereas its average is $1.3 million.
  • Per our database at Business Quant, Marimed's Depreciation and Depletion skyrocketed by 9000.0% in 2024 and then plummeted by 526.32% in 2025.
  • Quarter analysis of 5 years shows Marimed's Depreciation and Depletion stood at $600682.0 in 2021, then surged by 49.83% to $900000.0 in 2022, then soared by 88.89% to $1.7 million in 2023, then rose by 29.41% to $2.2 million in 2024, then fell by 4.55% to $2.1 million in 2025.
  • Its Depreciation and Depletion was $2.1 million in Q3 2025, compared to $2.1 million in Q2 2025 and $1.8 million in Q1 2025.